Scaling Analysis of Affinity Propagation

We analyze and exploit some scaling properties of the Affinity Propagation (AP) clustering algorithm proposed by Frey and Dueck (2007). First we observe that a divide and conquer strategy, used on a large data set hierarchically reduces the complexity ${\cal O}(N^2)$ to ${\cal O}(N^{(h+2)/(h+1)})$, for a data-set of size $N$ and a depth $h$ of the hierarchical strategy. For a data-set embedded in a $d$-dimensional space, we show that this is obtained without notably damaging the precision except in dimension $d=2$. In fact, for $d$ larger than 2 the relative loss in precision scales like $N^{(2-d)/(h+1)d}$. Finally, under some conditions we observe that there is a value $s^*$ of the penalty coefficient, a free parameter used to fix the number of clusters, which separates a fragmentation phase (for $s<s^*$) from a coalescent one (for $s>s^*$) of the underlying hidden cluster structure. At this precise point holds a self-similarity property which can be exploited by the hierarchical strategy to actually locate its position. From this observation, a strategy based on \AP can be defined to find out how many clusters are present in a given dataset.Comment: 28 pages, 14 figures, Inria research repor

SPARC, a phase-I trial of pre‐operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer

Background and purpose: Following resection of pancreatic cancer, risk of positive margins and local recurrence remain high, especially for borderline-resectable pancreatic cancer (BRPC). We aimed to establish the maximum tolerated dose of a margin-intensified five-fraction stereotactic body radiotherapy (SBRT) regimen designed to treat the region at risk. / Materials and methods: We conducted a prospective multicentre phase-1 rolling-six dose-escalation study. BRPC patients received pre-operative SBRT, with one dose to the primary tumour and an integrated boost to the region where tumour was in contact with vasculature. Four dose-levels were proposed, with starting dose 30 Gy to primary PTV and 45 Gy to boost volume (PTV_R), in five daily fractions. Primary endpoint was maximum tolerated dose (MTD), defined as highest dose where zero of three or one of six patients experienced dose-limiting toxicity (DLT). / Results: Twelve patients were registered, eleven received SBRT. Radiotherapy was well tolerated with all treatment completed as scheduled. Dose was escalated one level up from starting dose without encountering any DLT (prescribed 32.5 Gy PTV, 47.5 Gy PTV_R). Nine serious adverse reactions or events occurred (seven CTCAE Grade 3, two Grade 4). Two patients went on to have surgical resection. Median overall survival for SBRT patients was 8.1 months. The study closed early when it was unable to recruit to schedule. / Conclusion: Toxicity of SBRT was low for the two dose-levels that were tested, but MTD was not established. Few patients subsequently underwent resection of pancreatic tumour after SBRT, and it is difficult to draw conclusions regarding the safety or toxicity of these therapies in combination

SPARC, a phase-I trial of pre‐operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer

Background and purpose: Following resection of pancreatic cancer, risk of positive margins and local recurrence remain high, especially for borderline-resectable pancreatic cancer (BRPC). We aimed to establish the maximum tolerated dose of a margin-intensified five-fraction stereotactic body radiotherapy (SBRT) regimen designed to treat the region at risk. / Materials and methods: We conducted a prospective multicentre phase-1 rolling-six dose-escalation study. BRPC patients received pre-operative SBRT, with one dose to the primary tumour and an integrated boost to the region where tumour was in contact with vasculature. Four dose-levels were proposed, with starting dose 30 Gy to primary PTV and 45 Gy to boost volume (PTV_R), in five daily fractions. Primary endpoint was maximum tolerated dose (MTD), defined as highest dose where zero of three or one of six patients experienced dose-limiting toxicity (DLT). / Results: Twelve patients were registered, eleven received SBRT. Radiotherapy was well tolerated with all treatment completed as scheduled. Dose was escalated one level up from starting dose without encountering any DLT (prescribed 32.5 Gy PTV, 47.5 Gy PTV_R). Nine serious adverse reactions or events occurred (seven CTCAE Grade 3, two Grade 4). Two patients went on to have surgical resection. Median overall survival for SBRT patients was 8.1 months. The study closed early when it was unable to recruit to schedule. / Conclusion: Toxicity of SBRT was low for the two dose-levels that were tested, but MTD was not established. Few patients subsequently underwent resection of pancreatic tumour after SBRT, and it is difficult to draw conclusions regarding the safety or toxicity of these therapies in combination

Using Datamining Techniques to Help Metaheuristics: A Short Survey

International audienceHybridizing metaheuristic approaches becomes a common way to improve the efficiency of optimization methods. Many hybridizations deal with the combination of several optimization methods. In this paper we are interested in another type of hybridization, where datamining approaches are combined within an optimization process. Hence, we propose to study the interest of combining metaheuristics and datamining through a short survey that enumerates the different opportunities of such combinations based on literature examples

Decoupling of topsoil and subsoil controls on organic matter dynamics in the Swiss Alps

Our understanding of mechanisms governing soil organic matter (OM) stability is evolving. It is gradually becoming accepted that soil OM stability is not primarily regulated by the molecular structure of plant inputs, but instead by the biotic and abiotic properties of the edaphic environment. Moreover, several experimental studies conducted in artificial systems have suggested that mechanisms regulating OM stability may differ with depth in the soil profile. Up to now however, there is very limited field-scale evidence regarding the hierarchy of controls on soil OM dynamics and their changes with soil depth. In this study, we take advantage of the high heterogeneity of ecological conditions occurring in the alpine belt to identify the major determinants of OM dynamics and how their significance varies with depth in the soil profile. Aboveground litter, mineral topsoil, and subsoil samples originating from 46 soil profiles spanning a wide range of soil and vegetation types were analysed. We used Rock-Eval pyrolysis, a technique that investigates the thermal stability of OM, as an indicator of OM dynamics. Our results show a clear divergence in predictors of OM thermal stability in the litter, topsoil, and subsoil layers. The composition of OM correlated with its thermal stability in the litter layer but not in mineral soil horizons, where the supply rate of fresh organic material and the physical and chemical characteristics of the pedogenic environment appeared important instead. This study offers direct confirmation that soil OM dynamics are influenced by different ecosystem properties in each soil layer. This has important implications for our understanding of carbon cycling in soils under a changing climate

NEOSCOPE: A randomized phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma

Background: Oxaliplatin-capecitabine (OxCap) and carboplatin-paclitaxel (CarPac) based neo-adjuvant chemoradiotherapy (nCRT) have shown promising activity in localised, resectable oesophageal cancer. Patients and methods: A non-blinded, randomised (1:1 via a centralised computer system), ‘pick a winner’ phase II trial. Patients with resectable oesophageal adenocarcinoma ≥ cT3 and/or ≥ cN1 were randomised to OxCapRT (oxaliplatin 85 mg/m2 day 1, 15, 29; capecitabine 625 mg/m2 bd on days of radiotherapy) or CarPacRT (carboplatin AUC2; paclitaxel 50 mg/m2 day 1, 8, 15, 22, 29). Radiotherapy dose was 45 Gy/25 fractions/5 weeks. Both arms received induction OxCap chemotherapy (2 × 3 week cycles of oxaliplatin 130 mg/m2 day 1, capecitabine 625 mg/m2 bd days 1–21). Surgery was performed 6–8 weeks after nCRT. Primary end-point was pathological complete response (pCR). Secondary end-points included toxicity, surgical morbidity/mortality, resection rate and overall survival. Statistics: Based on pCR ≤ 15% not warranting future investigation, but pCR ≥ 35% would, 76 patients (38/arm) gave 90% power (one-sided alpha 10%), implying that arm(s) having ≥10 pCR out of first 38 patients could be considered for phase III trials. ClinicalTrials.gov: NCT01843829. Funder: Cancer Research UK (C44694/A14614). Results: Eighty five patients were randomised between October 2013 and February 2015 from 17 UK centres. Three of 85 (3.5%) died during induction chemotherapy. Seventy-seven patients (OxCapRT = 36; CarPacRT = 41) underwent surgery. The 30-d post-operative mortality was 2/77 (2.6%). Grade III/IV toxicity was comparable between arms, although neutropenia was higher in the CarPacRT arm (21.4% versus 2.6%, p = 0.01). Twelve of 41 (29.3%) (10 of first 38 patients) and 4/36 (11.1%) achieved pCR in the CarPacRT and OxcapRT arms, respectively. Corresponding R0 resection rates were 33/41 (80.5%) and 26/36 (72.2%), respectively. Conclusion: Both regimens were well tolerated. Only CarPacRT passed the predefined pCR criteria for further investigation